AtriCure reported strong second-quarter results with a 19.4% increase in worldwide revenue year-over-year. The company's net loss improved significantly, and it achieved positive adjusted EBITDA.
Worldwide revenue increased by 19.4% year-over-year to $100.9 million.
U.S. revenue grew by 19.1% year-over-year to $84.9 million.
Net loss improved by $9.7 million year-over-year.
Adjusted EBITDA was positive at $8.0 million, an improvement of $11.2 million year-over-year.
AtriCure projects full year 2023 revenue to be $392 million to $395 million, reflecting growth of approximately 19% to 20% over full year 2022. Management now expects full year 2023 positive adjusted EBITDA of approximately $12 million, and full year 2023 adjusted loss per share of approximately $0.92 to $0.94.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance